{
    "success": true,
    "data": {
        "id": 1609682,
        "msgid": "haier-biomedical-holds-european-partner-summit-in-rome-strengthening-in-europe-for-europe-strategy-1773370329",
        "date": "2026-03-13 09:26:28",
        "title": "Haier Biomedical Holds European Partner Summit in Rome, Strengthening \"In Europe, for Europe\" Strategy",
        "author": "",
        "source": "ANTARA_ID",
        "tags": "",
        "topic": "Business",
        "summary": "Haier Biomedical held its European Partner Summit in Rome, bringing together 37 regional partners and industry leaders from 23 European countries to discuss long-term commitment and introduce an expanded laboratory solutions portfolio aligned with the \"In Europe, for Europe\" strategy. The company targets over 50% of global revenue from international markets by 2027 and unveiled key innovations including the Plasma Apheresis System XJ-III with EU MDR certification, alongside automated biobank solutions and intelligent blood management systems. Haier Biomedical reported international revenue of RMB 840 million in 2025 (36% of total revenue), with European markets achieving double-digit growth.",
        "content": "<p>Rome \u2014 Haier Biomedical recently held its European Partner Summit in\nRome under the theme \u201cAdvancing Together \u2013 Sharing the Future of\nBiomedical Innovation\u201d. The event brought together 37 regional partners\nand industry leaders from 23 European countries to discuss the company\u2019s\nlong-term commitment to the region and introduce a broader portfolio of\nlaboratory solutions as part of an enhanced brand strategy. The new\nstrategy focuses on scenario-based and application-specific solutions,\nalong with Haier Biomedical\u2019s long-term plans to increase localisation\nin Europe to provide more comprehensive services and support tailored to\nregional market needs.<\/p>\n<p>Global Vision and European Market Strategy<\/p>\n<p>At the event, Enrique Wang, Global Market Director at Haier\nBiomedical, affirmed the company\u2019s global vision, targeting more than\n50% of global revenue from international markets by 2027, and more than\n50% of revenue from non-refrigeration products by 2028. He emphasised\nthat Europe represents a strategic market in the company\u2019s global\nexpansion roadmap through the \u201cIn Europe, for Europe\u201d principle. To this\nend, Haier Biomedical is delivering products, services, and support\ntailored to regional regulatory standards, customer expectations, and\napplication requirements.<\/p>\n<p>Presenting the European strategy for 2026, Semir Selimovic, Director\nof Northern, Central and Eastern Europe at Haier Biomedical Europe,\nhighlighted the company\u2019s commitment to continue investing in local\nsales teams, after-sales service, and product expertise to improve\nresponsiveness and execution across major markets. Europe has become one\nof the fastest-growing international regions for Haier Biomedical,\nsupported by local team expansion and a continuously developing product\nportfolio.<\/p>\n<p>Expansion from Freezer Products to Integrated Solutions<\/p>\n<p>Among the new products introduced by Haier Biomedical, the Plasma\nApheresis System XJ-III attracted considerable attention. The system has\nobtained EU MDR certification, an important achievement in meeting\nstrict European regulatory standards whilst strengthening Haier\nBiomedical\u2019s position in blood and plasma technology. Across Europe, the\nmarket share of Haier Biomedical\u2019s CO\u2082 incubators, centrifuges,\nbiosafety cabinets, and ultra-low temperature storage systems continues\nto expand. This is supported by energy-efficient technology and\ncompliance with various regional certification standards. The product\nevolution presented in Rome demonstrates Haier Biomedical\u2019s progress\ntowards a comprehensive solution portfolio supporting laboratories,\nhospitals, and life science institutions.<\/p>\n<p>Automation and Intelligent Blood Management as Growth Drivers<\/p>\n<p>Daniele Pericolini, European Automation Solution Specialist at Haier\nBiomedical, outlined the company\u2019s strategy to drive future growth\nthrough laboratory automation and intelligent blood management systems.\nHaier Biomedical\u2019s automatic biobank solutions integrate ultra-low\ntemperature storage with RFID-based systems, modular automation\nplatforms, and liquid nitrogen systems to enhance sample tracking and\noperational efficiency. These solutions address challenges such as\nsample integrity, temperature monitoring, and high-capacity storage\nrequirements, thereby strengthening Haier Biomedical\u2019s position amid\nsurging demand for biobank infrastructure in Europe.<\/p>\n<p>Additionally, the U-Blood intelligent blood management system\nintroduces a new approach to blood supply chain management. The system\ntransforms conventional blood storage methods into real-time connected\nblood supply chain management, reducing waste, improving tracking, and\nsupporting 24-hour transfusion services. This solution also aligns with\nEurope\u2019s focus on safety, digitalisation, and zero-waste healthcare\ninitiatives.<\/p>\n<p>Customer Recognition Across Europe and Brand Alignment<\/p>\n<p>During the meeting, partners from Germany, Slovenia, France, and\nDenmark shared experiences using Haier Biomedical solutions in their\nlocal markets. In France, a long-term Haier Biomedical partner presented\na biosafety cabinet developed jointly with Haier Biomedical according to\nnational standards. Over 230 units of this biosafety cabinet have been\ndeployed to more than 100 customers. In Denmark, a biosafety cabinet\npartner reported successful sales of ultra-low temperature freezers\nthrough various public tenders and expansion into additional product\ncategories. Meanwhile, a large-scale installation in the pharmaceutical\nsector in Slovenia demonstrates Haier Biomedical\u2019s capability to handle\ncomplex projects with multiple units. Central European partners also\nemphasised product reliability, regulatory compliance, and after-sales\nservice as competitive advantages for Haier Biomedical.<\/p>\n<p>Strong International Growth in 2025<\/p>\n<p>Haier Biomedical\u2019s expansion in Europe is supported by solid\nfinancial performance. In 2025, Haier Biomedical recorded revenue\nexceeding RMB 2.3 billion, whilst international revenue reached RMB 840\nmillion, contributing more than 36% of total revenue.<\/p>\n<p>The European market achieved double-digit growth, contributing\nsignificantly to the increase in international revenue. Additionally,\nAI-based and automation solutions accounted for approximately 15% of\ntotal revenue in 2025, indicating acceleration of technological\ntransformation. This performance reflects Haier Biomedical\u2019s strategic\nshift from simply exporting hardware to providing localised solutions\nsupported by regional teams and product certification in more than 18\ncountries.<\/p>\n<p>As the European Partner Summit concluded, Haier Biomedical reaffirmed\nits commitment to strengthen local operational activities in Europe,\nexpand automation and life science solutions, and drive shared growth\nwith its partners.<\/p>",
        "url": "https:\/\/jawawa.id\/newsitem\/haier-biomedical-holds-european-partner-summit-in-rome-strengthening-in-europe-for-europe-strategy-1773370329",
        "image": ""
    },
    "sponsor": "Okusi Associates",
    "sponsor_url": "https:\/\/okusiassociates.com"
}